An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack
NCT00330850
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
650
Enrollment
INDUSTRY
Sponsor class
Conditions
Migraine
Photophobia
Phonophobia
Interventions
DRUG:
PRO-513
Sponsor
ProEthic Pharmaceuticals